
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc’s innovative approach to treating autoimmune disorders is bolstered by its promising pipeline, particularly with A-005 demonstrating complete disease suppression in relevant models and exhibiting a favorable pharmacokinetic profile. The ongoing merger with Acelyrin is viewed positively by the Acelyrin board, indicating confidence in maximizing long-term value, which may enhance Alumis’s market position. Furthermore, ESK-001's updated efficacy data suggests strong potential market penetration that could surpass competition, further solidifying a favorable outlook for Alumis's future financial performance.
Bears say
Alumis Inc faces significant risks that contribute to a negative outlook on its stock, particularly concerning the advancement of its lead candidate, ESK-001, into pivotal trials, which could be delayed. There are substantial concerns regarding the clinical efficacy of ESK-001 in psoriasis (PsO) and systemic lupus erythematosus (SLE) trials, alongside hurdles in securing regulatory approvals in key markets that are critical for revenue generation. Furthermore, the competitive landscape within the immunology and inflammation (I&I) therapeutic sector poses additional threats, compounded by the potential for slower-than-expected market uptake and dilution risks affecting shareholder value.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares